Yoshinori Mizuguchi

Dr. Yoshinori Mizuguchi

Metabologenomics, Inc.

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2020 in Biomacromolecules
Verified
Journal Article
Closed access
YMYoshinori Mizuguchi
Yoshinori Mizuguchi
YMYasumasa Mashimo
Yasumasa Mashimo
MMMasayasu Mie
Masayasu Mie
EKEiry Kobatake
Eiry Kobatake

26 June 2015 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
YAYasmine Assal
Yasmine Assal
YMYoshinori Mizuguchi
Yoshinori Mizuguchi
MMMasayasu Mie
Masayasu Mie
EKEiry Kobatake
Eiry Kobatake

27 August 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
AWAyako Watanabe
Ayako Watanabe
TTTakumi Tochio
Takumi Tochio
YKYoshihiro Kadota
Yoshihiro Kadota
MTMotoki Takahashi
Motoki Takahashi
YKYasuyuki Kitaura
Yasuyuki Kitaura
YSYoshiharu Shimomura
Yoshiharu Shimomura
Insulin resistance leads to the onset of medical conditions such as type 2 diabetes, and its development is associated with the alteration in the gut microbiota. Although it has been demonstrated that supplementation with prebiotics modulates the gut microbiota, limited evidence is available for effects of prebiotics on insulin resistance, especially for humans. We investigated the prebiotic effect of 1-kestose supplementation on fasting insulin concentration in obesity-prone humans and rats. In the preliminary study using rats, the hyperinsulinemia induced by high-fat diet was suppressed by intake of water with 2% (w/v) 1-kestose. In the clinical study using obese-prone volunteers, the fasting serum insulin level was significantly reduced from 6.5 µU/mL (95% CI, 5.5–7.6) to 5.3 (4.6–6.0) by the 12-week intervention with supplementation of 10 g 1-kestose/day, whereas it was not changed by the intervention with placebo (6.2 µU/mL (5.4–7.1) and 6.5 (5.5–7.6) before and after intervention, respectively). The relative abundance of fecal Bifidobacterium was significantly increased to 0.3244 (SD, 0.1526) in 1-kestose-supplemented participants compared to that in control participants (0.1971 (0.1158)). These results suggest that prebiotic intervention using 1–kestose may potentially ameliorate insulin resistance in overweight humans via the modulation of the gut microbiota. UMIN 000028824.

15 February 2022 in Foods
Verified
Journal Article
Open access
PDF file
HMHiroshi Matsuoka
Hiroshi Matsuoka
TTTakumi Tochio
Takumi Tochio
AWAyako Watanabe
Ayako Watanabe
KFKohei Funasaka
Kohei Funasaka
YHYoshiki Hirooka
Yoshiki Hirooka
IMIsao Morita
Isao Morita
Enteral nutrition (EN) is a rational approach to providing nutritional intake via the intestines in patients who are unable to tolerate parenteral nutrition. We conducted a preliminary study to investigate the effects of EN on the intestinal environment in 10 patients in a persistent vegetative state (PVS) (n = 5 each in the EN and EN with probiotics; Clostridium butyricum MIYAIRI 588) groups compared with 10 healthy controls. The results of 16S amplicon sequencing of the intestinal microbiota showed that EN led to dysbiosis with a decrease in α-diversity and an obvious change in β-diversity. A particularly significant decrease was seen in useful intestinal bacteria such as Bifidobacterium and butyrate-producing bacteria. Analysis of intestinal metabolites also supported these results, showing significant decreases in butyric and pyruvic acid after EN. Although C. butyricumMIYAIRI 588 improved some intestinal metabolites that were decreased after EN, it did not improve the dysbiosis of the intestinal microbiota. These findings indicate that EN causes dysbiosis of the intestinal microbiota and an imbalance in some intestinal metabolites in patients in a PVS. Moreover, although C. butyricumMIYAIRI 588 improved the imbalance of some intestinal metabolites after EN, it did not prevent dysbiosis of the intestinal microbiota.

1 August 2017 in Biomedical Materials
Verified
Journal Article
Closed access
PDF file
YMYoshinori Mizuguchi
Yoshinori Mizuguchi
YMYasumasa Mashimo
Yasumasa Mashimo
MMMasayasu Mie
Masayasu Mie
EKEiry Kobatake
Eiry Kobatake
Self-assembling peptides are attractive materials for tissue engineering applications because of their functionality including high biocompatibility and biodegradability. Modification of self-assembling peptides with functional motifs, such as the cell-adhesive tripeptide sequence RGD leads to functional artificial extracellular matrices (ECMs). In this study, we developed an artificial self-assembling ECM protein tethered with a growth factor via heterotrimer triple-helix (helix A/B/C) formation. The helix A and helix C peptides, which are capable of forming a heterodimer coiled-coil structure, were fused to both ends of a matrix protein composed of the elastin-derived structural unit (APGVGV) 12 with an RGD motif. The helix B peptide, which constituents the third helix of the triple-helix structure, was fused with basic fibroblast growth factor (bFGF) for tethering to the artificial ECM proteins. Each recombinant protein exhibited cell adhesion and cell proliferation activities similar to the original, while the designed bFGF-tethered ECM protein exhibited superior cell proliferation activity. These results demonstrate that the approach of creating growth factor-tethered self-assembling proteins via triple-helix formation can be applied to develop functional ECMs for tissue engineering applications.

2 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
YNYuichiro Nishimoto
Yuichiro Nishimoto
YMYoshinori Mizuguchi
Yoshinori Mizuguchi
YMYuka Mori
Yuka Mori
MIMasaki Ito
Masaki Ito
SMShoko Miyazato
Shoko Miyazato
SFShinji Fukuda
Shinji Fukuda
Objective: In recent years, there have been many reports on the effects of prebiotics on intestinal health. In particular, consuming resistant maltodextrin (RMD) has been reported to be beneficial. However, there has been no comprehensive quantification of the effect of RMD on the intestinal environment. Therefore, this study aimed to quantify the effects of RMD on the intestine, especially the intestinal microbiome and metabolome profiles. Design: A randomized, double-blind controlled trial was conducted in 29 Japanese subjects with relatively high hemoglobin A1c (HbA1c). Subjects consumed RMD or placebo twice per day for 24 weeks. Blood and fecal samples were collected before and after intake. The intestinal environment was assessed by a metabologenomics approach combined with 16S rRNA gene-based microbiome and mass spectrometry-based metabologenomics analyses. Results: The intake of RMD increased the levels of Bifidobacterium and Fusicatenibacter , and decreased deoxycholate. In addition, intake of the RMD lowered the levels of some virulent metabolites, such as imidazole propionate and trimethylamine, in subjects with an initially high amount of those metabolites. Conclusion: RMD may have beneficial effects on the gut environment such as commensal microbiota modulation and reduction of virulence metabolites, known as a causative factor in metabolic disorders. However, its effect partially depends on the gut environmental baseline.